Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Finished Goods: 2021-2025

Historic Finished Goods for Rhythm Pharmaceuticals (RYTM) over the last 3 years, with Sep 2025 value amounting to $14.5 million.

  • Rhythm Pharmaceuticals' Finished Goods rose 80.97% to $14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year increase of 80.97%. This contributed to the annual value of $10.7 million for FY2024, which is 270.12% up from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Finished Goods stood at $14.5 million, which was up 6.70% from $13.6 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Finished Goods ranged from a high of $14.5 million in Q3 2025 and a low of $111,000 during Q4 2021.
  • For the 3-year period, Rhythm Pharmaceuticals' Finished Goods averaged around $6.7 million, with its median value being $5.9 million (2024).
  • Data for Rhythm Pharmaceuticals' Finished Goods shows a peak YoY skyrocketed of 1,384.62% (in 2023) over the last 5 years.
  • Over the past 5 years, Rhythm Pharmaceuticals' Finished Goods (Quarterly) stood at $111,000 in 2021, then spiked by 75.68% to $195,000 in 2022, then soared by 1,384.62% to $2.9 million in 2023, then surged by 270.12% to $10.7 million in 2024, then skyrocketed by 80.97% to $14.5 million in 2025.
  • Its Finished Goods was $14.5 million in Q3 2025, compared to $13.6 million in Q2 2025 and $12.6 million in Q1 2025.